[P1–099]: SCREENING FDA‐APPROVED COMPOUNDS IN A TREM2 CELL MODEL OF ALZHEIMER's DISEASE | Zendy

Rutter Hannah | Zendy; Lim Yau Mun | Zendy; Corcoran Jonathan | Zendy; Hodges Angela | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

[P1–099]: SCREENING FDA‐APPROVED COMPOUNDS IN A TREM2 CELL MODEL OF ALZHEIMER's DISEASE

Author(s) -

Rutter Hannah,

Lim Yau Mun,

Corcoran Jonathan,

Hodges Angela

Publication year - 2017

Publication title -

alzheimer's and dementia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.713

H-Index - 118

eISSN - 1552-5279

pISSN - 1552-5260

DOI - 10.1016/j.jalz.2017.06.166

Subject(s) - trem2 , microglia , neuroprotection , receptor , phagocytosis , pharmacology , biology , immunology , cancer research , inflammation , biochemistry

P1-099 SCREENING FDA-APPROVED COMPOUNDS IN ATREM2 CELL MODEL OFALZHEIMER’S DISEASE Hannah Rutter, Yau Mun Lim, Jonathan Corcoran, Angela Hodges, King’s College London, Institute of Psychiatry, Psychology & Neuroscience, London, United Kingdom; King’s College London, Wolfson Centre of Age-Related Disease, London, United Kingdom; Maurice Wohl Clinical Neuroscience Institute James Black Centre Institute of Psychiatry, Psychology & Neuroscience (IoPPN) King’s College, London, United Kingdom. Contact e-mail: hannah.rutter@kcl.ac.uk

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research